Gastrointestinal Cancer
From the Journals
Genetic Biomarker May Predict Pancreatic Adenocarcinoma Outcomes
Decreased messenger RNA sequencing expression of SMAD4 was associated with lower overall survival.
From the Journals
Do Multivitamin Supplements Lower Mortality Risk in CRC?
Researchers assess whether multivitamin use affects overall survival among people with CRC.
Conference Coverage
Regrowth Predicts Metastasis in Rectal Cancer Watch and Wait
Investigators compared outcomes for ‘watch-and-wait’ patients with those who had total mesorectal excisions after neoadjuvant therapy.
Latest News
Treatment Sequence May Impact Pancreatic Cancer Survival
Researchers evaluated whether treatment sequence could affect survival outcomes in patients with unresectable and/or metastatic pancreatic ductal...
Conference Coverage
ctDNA’s Prognostic Strength, Low Sensitivity Seen in Studies
The test has excellent prognostic value for colorectal cancer, but clinicians aren’t ready to commit to using it to deescalate adjuvant therapy....
Feature
Dana-Farber Moves to Retract, Correct Dozens of Cancer Papers Amid Allegations
Dana-Farber Cancer Institute retracts six papers and corrects more than 30 after data changes found.
Conference Coverage
Bladder Cancer: Is Active Surveillance the Way Forward?
Should clinicians promote active surveillance for non–muscle-invasive bladder tumors (NMIBT) and establish it as a comprehensive management...
Conference Coverage
The Case for Biomarker Testing in Gastroesophageal Cancer
Expert provides top three picks for biomarker testing for treatment selection.
Conference Coverage
Hepatic infusion pumps: New enthusiasm for an old technology
The response with the pump is “clearly superior” to systemic treatment, according to the author a new study.
Conference Coverage
Targeted Colorectal Cancer Combo Improves QoL
The results of a new trial may point the way to other dual therapies involving kinase inhibitors, says expert.
Conference Coverage
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
The findings of a new study indicate that nivolumab plus ipilimumab should really be “a new standard,” a medical oncologist says.